The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)
Sponsor study identifier
observational
300
2 countries
2
Study Start
October 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
It is recognized that endothelial dysfunction is a major factor contributing to the atherogenic process. Abnormal function of the endothelium is detectable prior to obvious intimal lesions in patients with risk factors for atherosclerosis. Endothelial dysfunction is a systemic disorder and a key variable in the pathogenesis of atherosclerosis and its complications. Measurement of peripheral vasodilator response with fingertip peripheral arterial tonometry (PAT) technology (EndoPAT; Itamar Medical, Caesarea, Israel) is emerging as a useful method for assessing vascular function. EndoPAT may be a potential valid test increasing the accuracy, sensitivity and specificity for detection of subjects to chest pain unit (CPU) with chest pain but no obvious coronary artery disease (CAD). This is a relatively fast non-invasive bedside test, relatively low-cost and has no side effects. Therefore, the primary objective of the study is to test the hypothesis that abnormal endothelial function as assessed by EndoPAT testing will increase the prediction of the short (in-hospital) and long-term (1-year) outcome of patients presenting to the chest pain unit.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 10, 2012
Actual (reported)June 13, 2012
Actual (reported)October 2012
Date type not reportedThis date has not been verified as actual or estimated.
December 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
December 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The association of EndoPat and short-term and long-term outcomes
To test the hypothesis that abnormal endothelial function as assessed by EndoPAT testing will increase the prediction of the short (in-hospital) and long-term (1-year) outcome of patients presenting to the chest pain unit.
1 and 2 years
The comparison of different imaging modalities on short- and long-term outcomes
1 and 2 years
All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
Mayo Clinic Chest Pain Unit, Emergency Department
Rochester, Minnesota, 55905, United States
Chest Pain Unit, Chaim Sheba Emergency Department
Tel Litwinsky, 52621, Israel
Shechter M, Natanzon SS, Lerman A, Cohn H, Prasad M, Goitein O, Goldkorn R, Naroditsky M, Koren-Morag N, Matetzky S. Endothelial function predicts 5-year adverse outcome in patients hospitalized in an emergency department chest pain unit. J Cardiovasc Med (Hagerstown). 2023 Oct 1;24(10):729-736. doi: 10.2459/JCM.0000000000001502. Epub 2023 May 18.
Michael Shechter, MD
Chaim Sheba Medical Center
Shlomi Matetzky, MD
Chaim Sheba Medical Center
Amir Lerman, MD
Mayo Clinic
Joerg Herman, MD
Mayo Clinic
First Submitted
June 10, 2012
First Posted
June 13, 2012
Study Start
October 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2025
Estimated (date passed)Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 12, 2023
Record last verified: 2023-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: